BR112015020918A2 - methods to treat hcv - Google Patents
methods to treat hcvInfo
- Publication number
- BR112015020918A2 BR112015020918A2 BR112015020918A BR112015020918A BR112015020918A2 BR 112015020918 A2 BR112015020918 A2 BR 112015020918A2 BR 112015020918 A BR112015020918 A BR 112015020918A BR 112015020918 A BR112015020918 A BR 112015020918A BR 112015020918 A2 BR112015020918 A2 BR 112015020918A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- hcv
- methods
- weeks
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000003443 antiviral agent Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
resumo métodos para tratar o hcv a presente invenção inclui terapias sem interferon para o tratamento do hcv. de preferência, o tratamento tem uma duração mais curta, tal como de não mais que 12 semanas. em um aspecto, o tratamento compreende administrar ao menos dois agentes antivirais de atuação direta mais ribavirina a um paciente infec-tado pelo hcv, em que o tratamento dura 12 semanas e não inclui a administração de interferon, e os referidos ao menos dois agentes antivirais de atuação direta compreendem (a) o composto 1, ou um sal farmaceuticamente aceitável deste, e (b) o composto 2, ou um sal farmaceuticamente aceitável deste.abstract "methods for treating hcv" the present invention includes interferon-free therapies for the treatment of hcv. preferably, the treatment is of a shorter duration, such as no more than 12 weeks. in one aspect, the treatment comprises administering at least two direct-acting antiviral agents plus ribavirin to an hcv-infected patient, wherein the treatment lasts for 12 weeks and does not include the administration of interferon, and said at least two antiviral agents Direct acting compounds comprise (a) compound 1, or a pharmaceutically acceptable salt thereof, and (b) compound 2, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361783437P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027556 WO2014152635A1 (en) | 2013-03-14 | 2014-03-14 | Combination of direct acting antiviral agents and ribavirin for treating hcv patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015020918A2 true BR112015020918A2 (en) | 2017-07-18 |
Family
ID=50771575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015020918A BR112015020918A2 (en) | 2013-03-14 | 2014-03-14 | methods to treat hcv |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20140274934A1 (en) |
| EP (4) | EP3733180A1 (en) |
| JP (3) | JP6563894B2 (en) |
| KR (2) | KR101853605B1 (en) |
| CN (3) | CN105007921B (en) |
| AU (3) | AU2014239322B2 (en) |
| BR (1) | BR112015020918A2 (en) |
| CA (1) | CA2901818C (en) |
| CY (1) | CY1121474T1 (en) |
| DK (1) | DK2968302T3 (en) |
| EA (2) | EA201890507A1 (en) |
| ES (1) | ES2654109T3 (en) |
| HK (2) | HK1213191A1 (en) |
| HR (1) | HRP20171898T1 (en) |
| HU (1) | HUE036069T2 (en) |
| IL (2) | IL240445B (en) |
| LT (1) | LT2968302T (en) |
| MX (1) | MX2015012536A (en) |
| NO (1) | NO3090119T3 (en) |
| PL (1) | PL2968302T4 (en) |
| PT (1) | PT2968302T (en) |
| RS (1) | RS56735B1 (en) |
| SG (2) | SG10201709840UA (en) |
| SI (1) | SI2968302T1 (en) |
| TW (2) | TWI678205B (en) |
| WO (1) | WO2014152635A1 (en) |
| ZA (1) | ZA201705080B (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| CN105007921B (en) * | 2013-03-14 | 2018-12-11 | 艾伯维公司 | For treating the antivirotic directly acted on and the combination of Ribavirin of HCV patient |
| CN105658219A (en) * | 2013-10-25 | 2016-06-08 | 艾伯维公司 | Methods for treating hcv |
| EP3082808A1 (en) * | 2013-12-19 | 2016-10-26 | AbbVie Inc. | Methods for treating liver transplant recipients |
| MX2016012722A (en) * | 2014-04-02 | 2016-12-16 | Abbvie Inc | Methods for treating hcv. |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
| DK3383662T3 (en) | 2016-01-08 | 2020-10-26 | Entrust Datacard Corp | CARD PRINTING MECHANISM WITH CARD RETURN ROAD |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| AU2017332771A1 (en) * | 2016-09-23 | 2019-04-04 | Abbvie Inc. | Dose adjustment |
| JP2018131439A (en) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Methods for treating hcv |
| CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
| CN108329332A (en) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | A method of preparing Glecaprevir |
| CN112351799A (en) * | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | Treatment of HCV infected patients with cirrhosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110053327A (en) * | 2008-06-10 | 2011-05-20 | 얀센 파마슈티카 엔.브이. | Telaprevir dosing regimen |
| CN102333772B (en) * | 2009-06-11 | 2013-12-11 | 雅培制药有限公司 | Anti-viral compounds |
| US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| SG188618A1 (en) * | 2010-09-21 | 2013-04-30 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
| CH707029B1 (en) | 2011-10-21 | 2015-03-13 | Abbvie Inc | A method of treating HCV comprising at least two direct acting antiviral agents, ribavirin but not interferon. |
| AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| CN105007921B (en) | 2013-03-14 | 2018-12-11 | 艾伯维公司 | For treating the antivirotic directly acted on and the combination of Ribavirin of HCV patient |
-
2014
- 2014-03-14 CN CN201480014994.0A patent/CN105007921B/en not_active Expired - Fee Related
- 2014-03-14 SG SG10201709840UA patent/SG10201709840UA/en unknown
- 2014-03-14 EA EA201890507A patent/EA201890507A1/en unknown
- 2014-03-14 HU HUE14725812A patent/HUE036069T2/en unknown
- 2014-03-14 CN CN201810204041.0A patent/CN108187056A/en active Pending
- 2014-03-14 RS RS20171264A patent/RS56735B1/en unknown
- 2014-03-14 ES ES14725812.3T patent/ES2654109T3/en active Active
- 2014-03-14 TW TW103109528A patent/TWI678205B/en not_active IP Right Cessation
- 2014-03-14 EA EA201591701A patent/EA030482B1/en not_active IP Right Cessation
- 2014-03-14 WO PCT/US2014/027556 patent/WO2014152635A1/en active Application Filing
- 2014-03-14 PT PT147258123T patent/PT2968302T/en unknown
- 2014-03-14 KR KR1020157029564A patent/KR101853605B1/en active IP Right Grant
- 2014-03-14 EP EP20167304.3A patent/EP3733180A1/en not_active Withdrawn
- 2014-03-14 SI SI201430517T patent/SI2968302T1/en unknown
- 2014-03-14 LT LTEP14725812.3T patent/LT2968302T/en unknown
- 2014-03-14 EP EP21172004.0A patent/EP3915559A1/en not_active Withdrawn
- 2014-03-14 EP EP17189252.4A patent/EP3318258B1/en not_active Revoked
- 2014-03-14 AU AU2014239322A patent/AU2014239322B2/en not_active Ceased
- 2014-03-14 MX MX2015012536A patent/MX2015012536A/en unknown
- 2014-03-14 CA CA2901818A patent/CA2901818C/en active Active
- 2014-03-14 JP JP2016502479A patent/JP6563894B2/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020187011379A patent/KR20180045055A/en active IP Right Grant
- 2014-03-14 EP EP14725812.3A patent/EP2968302B9/en not_active Revoked
- 2014-03-14 BR BR112015020918A patent/BR112015020918A2/en not_active Application Discontinuation
- 2014-03-14 US US14/210,858 patent/US20140274934A1/en not_active Abandoned
- 2014-03-14 SG SG11201507361YA patent/SG11201507361YA/en unknown
- 2014-03-14 DK DK14725812.3T patent/DK2968302T3/en active
- 2014-03-14 TW TW108114285A patent/TW202002979A/en unknown
- 2014-03-14 PL PL14725812T patent/PL2968302T4/en unknown
- 2014-03-14 CN CN201811345144.5A patent/CN109908353A/en active Pending
- 2014-12-19 NO NO14823980A patent/NO3090119T3/no unknown
-
2015
- 2015-08-09 IL IL240445A patent/IL240445B/en active IP Right Grant
-
2016
- 2016-02-02 HK HK16101220.2A patent/HK1213191A1/en not_active IP Right Cessation
-
2017
- 2017-07-26 ZA ZA2017/05080A patent/ZA201705080B/en unknown
- 2017-12-06 HR HRP20171898TT patent/HRP20171898T1/en unknown
- 2017-12-06 CY CY20171101278T patent/CY1121474T1/en unknown
-
2018
- 2018-04-12 AU AU2018202581A patent/AU2018202581B2/en not_active Ceased
- 2018-11-09 HK HK18114396.1A patent/HK1255257A1/en unknown
-
2019
- 2019-05-07 JP JP2019087535A patent/JP2019167347A/en active Pending
- 2019-07-08 IL IL267927A patent/IL267927A/en unknown
- 2019-07-24 JP JP2019135865A patent/JP2019214585A/en active Pending
-
2020
- 2020-03-05 AU AU2020201656A patent/AU2020201656A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015020918A2 (en) | methods to treat hcv | |
| BR112015023017A2 (en) | combination of two antivirals for the treatment of hepatitis c | |
| BR112016022976A8 (en) | methods for treating hcv | |
| BR112014005617A2 (en) | combination treatment (for example with abt-072 or abt -333) of daas for use in the treatment of hcv | |
| BR112018000383A2 (en) | methods to treat hcv | |
| PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
| BR112018003232A2 (en) | Combination therapies for cancer treatment | |
| MX2014003180A (en) | Methods for treating hcv. | |
| BR112016013961A2 (en) | angiotensin ii alone or in combination for the treatment of hypotension | |
| MX2015017953A (en) | Methods for treating hcv. | |
| BR112013007423A2 (en) | combination therapy with regard to the treatment of hcv infection | |
| BR112017006272A2 (en) | The medicine constituent for medical treatment of chronic ulcerative colitis | |
| BR112014019897A8 (en) | SPIRO[2.4]HEPTANES FOR THE TREATMENT OF FLAVIVIRID INFECTIONS | |
| MX2016012722A (en) | Methods for treating hcv. | |
| BR112019005456A2 (en) | pharmaceutical composition and method for treating nonalcoholic hepatic steatosis | |
| BR102017022849A8 (en) | THERAPEUTIC USES OF DIRECT-ACTING ANTIVIRAL AGENTS TO TREAT OR PREVENT AN INFECTION WITH HEPATITIS C VIRUS GENOTYPE 1 TO 6 | |
| BR112017028488A2 (en) | methods to treat hcv | |
| MX2018001905A (en) | Methods for treating hcv. | |
| BR112018002433A2 (en) | pharmaceutical composition for migraine treatment | |
| BR112014026706A2 (en) | treatment method for steroid responsive dermatoses | |
| AU2019384793A8 (en) | Methods for treating acute HCV | |
| EA201401274A1 (en) | METHOD OF COMPLEX TREATMENT AND CORRECTION OF DISORDERS OF ISCHEMIC GENESIS IN LIVER RESECTIONS | |
| NZ631789A (en) | Combination of direct acting antiviral agents and ribavirin for treating hcv patients | |
| UA101772U (en) | METHOD OF TREATMENT OF CHRONIC Viral HEPATITIS WITH CONSOLIDATED NON-ALCOHOLIC LIVER DISEASE | |
| ES2572355A2 (en) | Combination of adf for use in the treatment of hcv (Machine-translation by Google Translate, not legally binding) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |